Nektar Therapeutics (NKTR)
Nasdaq: NKTR · Pharmaceutical Preparations · San Francisco, CA · filing with the SEC since 1996
Who owns Nektar Therapeutics
As filed with the SECHolders of 5% or more
5
Fmr LLC holds 15% of COMMON STOCK, as its SCHEDULE 13G/A filed May 6, 2026 says.
Directors and officers
9
report now, of 23 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed May 6, 2026 · COMMON STOCK · 11.1% in Mar 6, 2026
Two Seas Capital LP
SCHEDULE 13G/A · filed Sep 28, 2026 · Common Stock, $0.0001 par value · 9.1% in Aug 14, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock · 1.6% in Jul 18, 2025
Bvf Partners L P/il
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value · 9.8% in May 15, 2026
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
G1 Execution Services, LLC
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.3% in Nov 13, 2025
Eventide Asset Management, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value · reported falling below 5%
Millennium Management LLC
SCHEDULE 13G/A · filed Oct 28, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.4% in Jul 3, 2025
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.0001 par value · reported falling below 5%, from 5.72% in Aug 14, 2025
Deep Track Capital, LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 5.04% in Jan 30, 2026
TCG Crossover GP II, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 9.3% in Aug 14, 2025
Samlyn Capital, LLC
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.0001 par value · reported falling below 5%, from 5.2% in Feb 14, 2025
What NKTR reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Gannet Bio Chem
An investee · investee · invested in, named in the 10-K filed Mar 13, 2026
Insider tradesForm 4
16sales
0purchases
7sales on a scheduled plan
3people selling
$2.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 26 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Robin Howard W | President & CEO | 8 | $1.4M | 4 | 0 | $0 |
| Zalevsky Jonathan | Chief R&D Officer | 7 | $1.0M | 3 | 0 | $0 |
| Wilson Mark Andrew | Chief Legal Officer | 1 | $0 | 0 | 0 | $0 |